Activist hedge fund Starboard nominates five directors to Bristol-Myers board

10:05 AM ET Wed, 20 Feb 2019

CNBC's David Faber reports on the latest news regarding the Bristol-Myers acquisition of Celgene. The company announced in a press release that it will have a special shareholders meeting in April to vote on the Celgene deal. Activist hedge fund Starboard Value, which owns roughly $50 million of stock, has sent notice that it has nominated five directors to the company's board for its annual meeting.